Scientists create detailed map of Lymphoma's immune environment
NCT ID NCT04696692
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 60 people with diffuse large B-cell lymphoma who were starting standard chemotherapy (R-CHOP). Researchers used advanced single-cell technology to analyze tumor and blood samples over two years. The goal was to find biomarkers that could help predict how well treatment works and track disease changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Universitaire du Cancer Toulouse - Oncopole
Toulouse, 31059, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a Light-Based device spot dangerous infection risk without a blood draw?